Bausch + Lomb Replaces Brent Saunders Again, As Paragon And Verastem Reset Leadership

Bausch + Lomb’s leadership change was the most consequential move in a broader week of biotech executive reshuffling, with the eye health company announcing that CEO Brent Saunders is leaving less than four years into his latest tenure. The company said the exit was mutually agreed upon by Saunders and the board of directors.

Thomas Appio, CEO of parent company Bausch Health since 2022 and Bausch + Lomb chairperson as of August, will serve as interim CEO. In a statement, Saunders said that when he returned to Bausch + Lomb, he believed the company had tremendous potential and that it is now stronger, more focused and better positioned for the future with a clearer strategy, a more robust pipeline and significant opportunities ahead.

Evercore ISI analysts described the change as unexpected given the pipeline projections and commercial targets Bausch + Lomb had laid out. They also speculated that Appio’s interim takeover suggests the transition may have been a surprise to the company as well.

The Signal From The Biggest Moves

The Bausch + Lomb change stands out because it interrupts leadership at a moment when the company had already set expectations around pipeline progress and commercialization. An interim structure can preserve continuity, but it also leaves open how permanent leadership will align with the strategy already presented to investors.

At Paragon, the week’s appointments reflected a different kind of transition: post-deal talent capture. Four months after AbbVie announced its $10.9 billion deal to buy Apogee for its late-phase eczema drug zumilokibart, Paragon recruited Michael Henderson, M.D., who had led Apogee, to become its CEO. Henderson is joined by several former Apogee colleagues: head of R&D Carl Dambkowski, M.D.; chief business and financial officer Dan Mulreany; chief legal officer Matt Batters; and chief people officer Emily Cox.

Those hires have a direct corporate backstory. Zumilokibart was originally developed at Paragon before the Boston-based drug discovery hub spun out Apogee to advance the anti-IL-13 antibody. The leadership return suggests Paragon is reabsorbing experienced operators who already know its model and have recent experience taking an internally sourced asset through value-creating development and sale.

Other Notable Transitions

Verastem said Daniel Paterson will step down as CEO in the new year after 15 years in the role, with Michael Bailey set to take over. Paterson was involved in acquiring VS-7375 from GenFleet Therapeutics and in moving the program rapidly into phase 2 clinical trials across multiple KRAS G12D-mutated tumor types. VS-7375 is an oral KRAS G12D dual ON/OFF inhibitor that recently reported positive phase 1/2 data in multiple solid tumors, including metastatic pancreatic ductal adenocarcinoma. Bailey has served on Verastem’s board since May 2026 and previously spent 16 years at Aveo Pharmaceuticals in several leadership roles, including CEO.

Several other companies used leadership changes to mark technical or clinical inflection points. Shenandoah Therapeutics appointed Steve Worland, Ph.D., as CEO while co-founder Isabella Graef, M.D., moved to chief scientific officer as the company advances its lead oncology program toward IND-enabling studies. Harmony Biosciences named board member and COO Peter Anastasiou as president and CEO ahead of Jeffrey Dayno, M.D.’s end-of-year retirement. Matchpoint Therapeutics hired John O’Malley, M.D., Ph.D., as chief medical officer as it prepares to move its lead covalent small molecule candidate into the clinic.

Other moves included Prologue Medicines naming Stephen Harrison, Ph.D., chief scientific officer; Ailux appointing Llyod Miller, M.D., Ph.D., chief medical officer; MetaVia selecting Sarah Browne, M.D., as chief medical officer; Intellia Therapeutics naming Jing Marantz, M.D., Ph.D., chief medical officer; AL-S Pharma choosing Harry Welten as CEO; Sibylla Biotech appointing Usman Azam, M.D., as CEO while Lidia Pieri, Ph.D., became chief operating officer and Elena Ardini advanced to chief scientific officer; and Nimbus Therapeutics adding Lizabeth Leveille as chief business officer, Fang Wang, Ph.D., as senior vice president and head of biology, and Daniel Price, Ph.D., as senior vice president and head of chemistry.

Taken together, the week’s personnel changes were less about routine hiring than about how companies are staffing around strategic moments: unexpected CEO turnover at a commercial-stage company, executive reassembly after a major acquisition, and clinical-stage biotechs putting leaders in place ahead of IND work, phase 2 development or first commercialization efforts.